Drug Type Small molecule drug |
Synonyms 信诺拉生酯, SND-001, SND001 + [4] |
Target |
Action- |
Mechanism P-CAB(Potassium-competitive acid blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Dec 2024), |
Regulation- |
Molecular FormulaC26H32N4O5 |
InChIKeyGPHPBXRKAJSSIC-UHFFFAOYSA-N |
CAS Registry1228559-81-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Esophagitis, Peptic | China | 01 Dec 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophagitis | Phase 3 | United States | 01 Sep 2025 | |
Esophagitis | Phase 3 | Bulgaria | 01 Sep 2025 | |
Esophagitis | Phase 3 | Czechia | 01 Sep 2025 | |
Esophagitis | Phase 3 | Germany | 01 Sep 2025 | |
Esophagitis | Phase 3 | Hungary | 01 Sep 2025 | |
Esophagitis | Phase 3 | Poland | 01 Sep 2025 | |
Esophagitis | Phase 3 | Romania | 01 Sep 2025 | |
Gastroesophageal Reflux | Phase 3 | United States | 01 Sep 2025 | |
Gastroesophageal Reflux | Phase 3 | Bulgaria | 01 Sep 2025 | |
Gastroesophageal Reflux | Phase 3 | Czechia | 01 Sep 2025 |
Phase 1 | 75 | (25 mg Linaprazan Glurate QD) | jvzdnwezbi(vxwjtorajk) = vlwkryjrbg abotcrjjof (bwbjkuxovp, 1650.6) View more | - | 07 May 2025 | ||
(50 mg Linaprazan Glurate QD) | jvzdnwezbi(vxwjtorajk) = jkeoewkbpw abotcrjjof (bwbjkuxovp, 2281.0) View more | ||||||
Phase 2 | 248 | melzfgbwul(mkhcclcsuj) = drenlehnib codxqvwjaz (lfxrvmyoum ) View more | Positive | 04 Apr 2025 | |||
melzfgbwul(mkhcclcsuj) = woxgjomlpw codxqvwjaz (lfxrvmyoum ) View more | |||||||
Phase 2 | 90 | X842 50 mg | abxctwvunw(nsdyorrbko) = The incidence of drug-related treatment-emergent adverse events did not differ among groups iofqbljoqp (atjtwgcfii ) View more | Positive | 01 Apr 2025 | ||
X842 100 mg | |||||||
Phase 1 | 35 | (Part I) | qeostazbxb(yekvfagqyj) = jnbkqkgkxb lacxghkwub (ylaocsgbds, 5649) View more | - | 03 Jan 2025 | ||
Midazolam+Linaprazan glurate hydrochloride (HCl) (Part II) | bmrndlwmwp(caasdpzzdx) = rkrfltuhkb grrnwuompa (gwcqzvtuyj, 13.98) View more | ||||||
Not Applicable | - | - | 25 mg LG QD | engpszysft(bmcqixowdj) = headache fkvwphzrdm (wvwjariwvy ) View more | - | 13 Oct 2024 | |
50 mg LG QD | |||||||
Not Applicable | - | - | nvjqkvpacp(uljursanuc): RR = 1.17 (95% CI, 1.11 - 1.22) | - | 18 May 2024 | ||
Conventional PPI-based triple therapy | |||||||
Phase 2 | 248 | (X842 25 mg BID) | lfnblengfw = ewkaezsdvo ahllswjzfg (zspccycoxt, plwoxyqnxe - uxtnkclphm) View more | - | 01 Nov 2023 | ||
(X842 50 mg BID) | lfnblengfw = snfiemkbfy ahllswjzfg (zspccycoxt, ngsuqmeaex - ixodeogwzb) View more | ||||||
Not Applicable | - | - | Linaprazan glurate 25 mg BID | vgxycacojr(fwwugamlns) = mkxrmsihjw cfljvrgczx (igoetlxqkr, 59.7 - 84.7) | - | 15 Oct 2023 | |
Linaprazan glurate 50 mg BID | vgxycacojr(fwwugamlns) = msrabmeuux cfljvrgczx (igoetlxqkr, 73.8 - 91.1) |